RxDoctor Payments Data

Kyle Guidry, MD

Family Medicine · Thibodaux, LANPI 1619960812

Payments from drug & device makers

$8,613in general payments, 2019–2025

Across 558 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$942
  • GSK$855
  • Novo Nordisk$790
  • Lilly USA, LLC$691
  • Pfizer$495
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,605100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,613 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$206,246
Medicare patients
704
Services billed
8,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$80,918
OzempicSemaglutide56$54,606
FarxigaDapagliflozin Propanediol43$38,737
MounjaroTirzepatide33$36,724
EliquisApixaban46$33,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$31,605
JanuviaSitagliptin Phosphate23$24,594
TrulicityDulaglutide21$18,486
LinzessLinaclotide24$16,791
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,903
MyrbetriqMirabegron18$12,359
RybelsusSemaglutide12$11,141
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,178
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,598
SymbicortBudesonide/Formoterol Fumarate22$6,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$255$80,91875 claims
Novo NordiskOzempic, Rybelsus$790$65,74668 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$942$60,26186 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$691$57,24668 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$855$45,09672 claims
PfizerEliquis$495$33,94446 claims
MerckJanuvia$263$24,59423 claims
AbbVieLinzess, Armour Thyroid$1,588$18,62537 claims
Astellas Pharma US IncMyrbetriq$246$12,35918 claims
Sanofi-aventis U.S. LLCLantus$46$1,47819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →